UPDATED IN HEMATOLOGIC MALIGNANCIES
|
|
|
- Karen Booker
- 5 years ago
- Views:
Transcription
1 UPDATED IN HEMATOLOGIC MALIGNANCIES EKAPUN KAROOPONGSE MD DIVISION OF HEMATOLOGY, MEDICINE MAHIDOL UNIVERSITY
2 TREATMENT IN HEMATOLOGIC MALIGNANCIES Chemotherapy Immunotherapy Monoclonal antibody therapies Antibody-drug conjugates Immune checkpoint inhibitor Bispecific T cell engages (BITES) Chimeric Antigen Receptor (CAR) T cells
3 TREATMENT IN HEMATOLOGIC MALIGNANCIES Chemotherapy Immunotherapy Monoclonal antibody therapies : Multiple Myeloma Antibody-drug conjugates : Hodgkin lymphoma Immune checkpoint inhibitor : Hodgkin lymphoma Bispecific T cell engages (BITES) Chimeric Antigen Receptor (CAR) T cells : B-ALL
4 MONOCLONAL ANTIBODY Monoclonal Antibody in Hematologic malignancies Rituximab : B cell Non Hodgkin lymphoma Obinutuzumab : B cell Non Hodgkin lymphoma Daratumumab : Multiple Myeloma
5 DARATUMUMAB First in class, fully human IgG monoclonal antibody, target cell surface protein CD38
6 DARATUMUMAB AS A FIRST LINE ALCYONE trial Phase III, RCT in 706 patients with newly diagnosed multiple myeloma, ineligible for stem cell transplantation Compare between VMP and Daratumumab-VMP MV Mateos NEJM Dec 2016
7
8 DARATUMUMAB AS A FIRST LINE Median F/U 16.5 (0.1-28) months MV Mateos NEJM Dec 2016
9 DARATUMUMAB INTERFERENCE Daratumumab interference with laboratory testing Interfere serum protein electrophoresis (SPEP) and Immunofixation (IFE) Interfere with antibody screens and panreactivity on blood compatibility antibody screens MV Mateos NEJM Dec 2016
10 TREATMENT IN HEMATOLOGIC MALIGNANCIES Chemotherapy Immunotherapy Monoclonal antibody therapies : Multiple Myeloma Antibody-drug conjugates : Hodgkin lymphoma Immune checkpoint inhibitor : Hodgkin lymphoma Bispecific T cell engages (BITES) Chimeric Antigen Receptor (CAR) T cells : B-ALL
11 ANTIBODY-DRUG CONJUGATION Brentuximab Vedotin FDA approved for relapse/refractory Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL) A CD30-directed monoclonal antibody conjugated to microtubule polymerization monomethyl auristatin E (MMAE)
12 Advanced and Relapsed/Refractory Hodgkin Lymphoma: What Has Been Achieved During the Last 50 Years - Scientific Figure on ResearchGate. Available from: CD30-molecules-on-the_fig1_ [accessed 20 Aug, 2018]
13 ROLE OF BRENTUXIMAB IN HL Consolidation after ASCT (AETHERA trial) In relapsed/refractory Hodgkin Lymphoma Monotherapy in R/R after ASCT (phase II) Combination with bendamustine As frontline treatment in advance stage Hodgkin lymphoma (ECHELON-1)
14 PHASE II : BRENTUXIMAB IN PATIENT WITH R/R POST ASCT Younes A, JCO 2012
15 94% of patient achieved tumor reduction 75% achieved ORR, 34% achieved CR Younes A, JCO 2012
16 PHASE II : BRENTUXIMAB IN PATIENT WITH R/R POST ASCT Younes A, JCO 2012 \
17 AETHERA TRIAL Used as consolidation therapy after ASCT in high risk for relapse after ASCT Refractory to frontline Relapse < 12 mo after frontline Relapse > 12 mo after frontline with extranodal disease Phase III, randomized, double-blind multicenter study Prolonged PFS, reduce the risk of disease progression or death Moskowitz Blood PC, 2014 Lancet 124:
18 AETHERA TRIAL n 329 BV 1.8 mg/kg q 3 wk for up to 16 cycles Median number of treatment cycles was 15 28% progress, 19% AE The estimate 2-year PFS was 54% and 2- year OS was 88% Moskowitz PC, Lancet 2015
19 AETHERA TRIAL : LONG TERM RESULT Moskowitz ] PC, Lancet 2015
20 IMMUNE ESCAPE OR IMMUE EDITTING
21 IMMUNE ESCAPE : THE CONCEPT Immune system is a critical regulator to support or inhibitor tumor development, growth, in action and metastasis Major player : cytotoxic T cells
22
23 IMMUNOTHERAPY : CHECK POINT INHIBITOR
24 TREATMENT IN HEMATOLOGIC MALIGNANCIES Chemotherapy Immunotherapy Monoclonal antibody therapies : Multiple Myeloma Antibody-drug conjugates : Hodgkin lymphoma Immune checkpoint inhibitor : Hodgkin lymphoma Bispecific T cell engages (BITES) Chimeric Antigen Receptor (CAR) T cells : B-ALL
25 IMMUNOTHERAPY OF LYMPHOMA AND MULTIPLE MYELOMA Using host immune system to combat cancer Target immune checkpoint signaling pathway, enhance T cell cytotoxic activity and induce tumor cell lysis Immune check point inhibitor
26 IMMUNE CHECKPOINT Signals regulate an immune response
27 IMMUNE CHECKPOINT Immune responses by T cells are balanced by co-stimulators and inhibitory signals Coana TRMOME
28 IMMUNE CHECKPOINT Immune responses by T cells are balanced by co-stimulators and inhibitory signals Coana TRMOME
29 IMMUNE CHECK POINT INHIBITOR IN MALIGNANCIES TREATMENT Drugs Mechanism Indications Ipilimumab Anti-CTLA-4 antibody Advanced melanoma Pembrolizumab Nivolumab Anti-PD-1 Melanoma, metastatic NSCL, H&N SCCA, urothelial carcinoma, gastric adenocarcinoma, classical Hodgkin lymphoma Plus hepatocellular carcinoma, renal cell carcinoma Atezolizumab Anti-PD1-L1 Urothelial cancer, NSCLC
30 IMMUNE DEFICIENCY/INVASION IN HL T-cell qualitative defect T-cell quality defect : decrease proliferation and decrease IL-2 secretion Defect in T cell-mediated antitumor immune response Increase expression of programmed cell death-1 ligand 1 (PD-L1), and PD-L1 receptor on T cells
31
32 IMMUNOTHERAPY OF LYMPHOMA AND MULTIPLE MYELOMA Nivolumab Approved for refractory classical Hodgkin lymphoma 2016 Pembrolizumab FDA approved for RR HL after > 3 regimens 2017
33 NIVOLUMAB IN RR HL Trial N included refractory to BV Case series 75 response 64%, CR 22%, Multicenter phase II mo follow up Response 69%, Median PFS 14.7 Median duration of response 16.6.mo Nivolumab + Brentuximab Phase I % ORR, CR 62.5% H. Bekoz Annals of oncology 2017, Armand P. JCO 2018, Armand P Blood 2016, Diefenchah CS, Blood 2016
34 PEMBROLIZUMAB IN RR HL Trial N Pembrolizumab alone 1b 75 response 65%, CR 16%, Include failed BV Phase II 210 Response 69%, CR 22% Armand P JCO 2016, Chen R JCO 2017
35 IMMUNOTHERAPY : COMPLICATIONS Related to mechanism of action : immune-related adverse effect (iraes) Rash/inflammatory dermatitis/bullous dermatoses Colitis/Hepatitis Pneumonitis Inflammatory arthritis Nephritis Myasthenia gravis/peripheral neuropathy/encephalitis
36 TREATMENT IN HEMATOLOGIC MALIGNANCIES Chemotherapy Immunotherapy Monoclonal antibody therapies : Multiple Myeloma Antibody-drug conjugates : Hodgkin lymphoma Immune checkpoint inhibitor : Hodgkin lymphoma Bispecific T cell engages (BITES) Chimeric Antigen Receptor (CAR) T cells : B-ALL
37 BISPECIFIC T-CELL ENGAGES (BITES)
38 BITE Recombinant bispecific protein, two linked scfvs from two antibodies different One targeting a cell-surface molecule on T cells and the other targeting antigens on the surface of malignant cells
39 BLINATUMOMAB (AMG103) Antibody construct direct against the pan-b cell antigen CD19 and the CD3 Frankel SR, Current opinion in chemical biology 2013
40 BLINUTUMUMAB IN RRDLBCL Phase I trial with indolent, mantle cell and diffuse large B cell lymphoma 4-8 weeks continuous IV 5 ug/m 2 /d first week, 15 ug/m 2 /d second week than 60 ug/m 2 /d first week 5/9 patients showed objective clinical response (4CR/CRu, 1 PR) Median response duration +182 days, longest current duration +428 days Viardot A. Blood 2011
41 BLINUTUMUMAB IN ALL Phase III multi-institutional trial, RCT in RRALL Compare between blinutumumab and CMT 34% vs 16% CR, 6-month event free survival were 31 vs 12% Kantarjian H. NEJM 2017
42 BLINUTUMUMAB IN ALL Kantarjian H. NEJM 2017
43 CYTOKINES RELEASE SYNDROME Unique toxicity for immune-based therapy Reported after BiTEs and CAR-T cell treatment Associated with increasing production of IL-6 and interferon gamma S&S : fever + rigor, myalgia, arthalgias, rash, N&V, tachypnea, hypoxemia, hypotension, bleeding, renal failure, liver injury, delirium, confusion, seizure
44 TREATMENT IN HEMATOLOGIC MALIGNANCIES Chemotherapy Immunotherapy Monoclonal antibody therapies : Multiple Myeloma Antibody-drug conjugates : Hodgkin lymphoma Immune checkpoint inhibitor : Hodgkin lymphoma Bispecific T cell engages (BITES) Chimeric Antigen Receptor (CAR) T cells : B-ALL
45 CHIMERIC ANTIGEN RECEPTOR T CELL (CAR-T CELL)
46 CHIMERIC ANTIGEN RECEPTOR T CELLS T cell-based adoptive immunotherapy Antibody single-chain fragment (scfv) Costimulatory signal (Complete T cell activation process) CD3z signaling signal
47 Zhao Z, acts pharmaceutica sinica 2018
48
49 CHIMERIC ANTIGEN RECEPTOR T CELLS Kochenderfer JN. Blood 2012
50 APPLICATIONS IN HEMATOLOGIC MALIGNANCIES CAR-T cell in ALL and CLL FDA approved for refractory B-cell ALL in 2017 Diffuse large B cell lymphoma in 2017
51 ELIANA TRIAL (GLOBAL PHASE II) In 68 children and young adult relapsed/refractory ALL Median f/u 6.2 months Tisagenlecleucel (KYMRIAH) was present in the blood and bone marrow and persisted beyond 2 years Cost 475,000 USD
52 JULIET TRIAL (GLOBAL PHASE II) Relapse/refractory DLBCL and DLBCL after tranformation from follicular lymphoma Single-arm multicenter, phase II, n = 68 50% response, 32% complete response Schuster SJ, ASH abstract 2017
53 ONGOING TRIALS OF CART-19 T CELLS High-risk multiple myeloma Chronic lymphocytic leukemia or small lymphocytic lymphoma Advanced lymphoid malignancies Relapsed and Refractory B cell Non-Hodgkin lymphoma
54 Q & A
RACING TOWARD A CURE FOR BLOOD CANCERS WITH NEW CARS (CAR-T CELL THERAPY)
RACING TOWARD A CURE FOR BLOOD CANCERS WITH NEW CARS (CAR-T CELL THERAPY) Larry D. Anderson, Jr, MD, PhD Internal Medicine Grand Rounds University of Texas Southwestern Medical Center March 9, 2018 This
Affimed Presents Data from Phase 1b Combination Study of AFM13 with Pembrolizumab at ASH
FOR IMMEDIATE RELEASE Affimed Presents Data from Phase 1b Combination Study of AFM13 with Pembrolizumab at ASH Completed dose-escalation shows combination of AFM13 and pembrolizumab is well-tolerated;
The Early Chimeric Antigen Receptor (CAR) T-cell Experience From An Academic Perspective. CARs: LEARNING TO DRIVE
The Early Chimeric Antigen Receptor (CAR) T-cell Experience From An Academic Perspective CARs: LEARNING TO DRIVE Jakub Svoboda, MD University of Pennsylvania Philadelphia, PA Cancer Drug Development Forum
Multiple Myeloma Update PMMNG 13 Feb Outline. Alfred Garfall MD Edward Stadtmauer MD
Multiple Update PMMNG 13 Feb 2016 Alfred Garfall MD Edward Stadtmauer MD Outline w Updates on existing/approved drugs for multiple myeloma w Updates on new/upcoming drugs and strategies for multiple myeloma
An Overview of Chimeric Antigen Receptor T-cells: CAR-T-ing Away Cancer
An Overview of Chimeric Antigen Receptor T-cells: CAR-T-ing Away Cancer Maxwell Brown, PharmD Clinical Pharmacy Manager, Hematopoietic Stem Cell Transplantation NewYork-Presbyterian/Weill Cornell Medical
Control Strategies for Antibody-based Immuno-oncology Products: It Starts with Product Design!
Control Strategies for Antibody-based Immuno-oncology Products: It Starts with Product Design! Marjorie Shapiro Office of Biotechnology Products/FDA WCBP 2017 January 25, 2017 Disclaimer The views presented
Immuno-Oncology Opportunities and Challenges In Moving Toward a Cure for Multiple Myeloma
Immuno-Oncology Opportunities and Challenges In Moving Toward a Cure for Multiple Myeloma Stanley R. Frankel, MD, FACP Corporate Vice President, Clinical R & D Head, Immuno-Oncology Celgene Cancer Progress
The science behind Betalutin : why is it unique? Roy H. Larsen PhD Sciencons AS, Oslo, Norway
The science behind Betalutin : why is it unique? Roy H. Larsen PhD Sciencons AS, Oslo, Norway Speaker credentials Roy H. Larsen, PhD >25 years of experience in research on targeted radionuclide therapy
Emerging treatments in Multiple myeloma. Josh Veatch Damian Green
Emerging treatments in Multiple myeloma Josh Veatch Damian Green Emerging treatments in multiple myeloma Introduction Daratumumab Elotuzumab PD 1 inhibitors HDAC inhibitors Other emerging therapies in
Immunotherapy in Hemato-Oncology
ESMO PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY ZURICH, SWITZERLAND, NOVEMBER 2-3, 2018 Immunotherapy in Hemato-Oncology Markus G. Manz Director Department of Hematology and Oncology, University Hospital
Innovating Antibodies, Improving Lives. 37 th Annual J.P. Morgan Healthcare Conference January 9, 2019
Innovating Antibodies, Improving Lives 37 th Annual J.P. Morgan Healthcare Conference January 9, 2019 Forward Looking Statement This presentation contains forward looking statements. The words believe,
Introducing a First-in-Class treatment for Non-Hodgkin Lymphoma Carnegie Healthcare Conference, March 17, 2016 Marco Renoldi, Chief Business Officer
Introducing a First-in-Class treatment for Non-Hodgkin Lymphoma Carnegie Healthcare Conference, March 17, 2016 Marco Renoldi, Chief Business Officer Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo,
Immunotherapy in Hemato-Oncology
ESMO Preceptorship Programme Immuno-Oncology From tumor immunology to clinical application 2-3 November 2016 Zurich - CH Immunotherapy in Hemato-Oncology Markus G. Manz Klinikdirektor Hämatologie USZ Leiter
Investor Update. Roche to present new data from its industry-leading haematology portfolio at the American Society of Hematology 2018 Annual Meeting
Investor Update Roche to present new data from its industry-leading haematology portfolio at the American Society of Hematology 2018 Annual Meeting Ten medicines featured in over 70 abstracts, including
Media Release. Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting
Media Release Basel, 01 November 2017 Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting Further results from emicizumab phase III
PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF SINGLE-AGENT BISPECIFIC ANTIBODY T CELL ENGAGER GBR 1342 IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF SINGLE-AGENT BISPECIFIC ANTIBODY T CELL ENGAGER GBR 1342 IN RELAPSED/REFRACTORY MULTIPLE MYELOMA JOSHUA RICHTER 1 ; MARTIN WERMKE 2 ; JOHN KAUH 3 ; JONATHAN BACK
PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF SINGLE-AGENT BISPECIFIC ANTIBODY T CELL ENGAGER GBR 1342 IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF SINGLE-AGENT BISPECIFIC ANTIBODY T CELL ENGAGER GBR 1342 IN RELAPSED/REFRACTORY MULTIPLE MYELOMA JOSHUA RICHTER 1 ; OLA LANDGREN 2 ; JOHN KAUH 3 ; JONATHAN BACK
CAR T-CELL THERAPIES WEBINAR. Scientific and Policy perspectives. 5 December :00-17:30 CET
CAR T-CELL THERAPIES Scientific and Policy perspectives WEBINAR 5 December 2017 16:00-17:30 CET Viviana Galli Coordinator, European Alliance for Responsible R&D and Affordable Medicines Tuna Mutis, MD,
Jefferies Healthcare Conference
0 Jefferies Healthcare Conference 3 June 2015 NASDAQ: CRIS Forward Looking & Other Important Cautionary Statements This presentation contains forward-looking statements for purposes of the safe harbor
GSK 916: anti-bcma ADC An exciting potential advance in the treatment of Multiple Myeloma
GSK 916: anti-bcma ADC An exciting potential advance in the treatment of Multiple Myeloma 12 December 2017 Cautionary statement regarding forward-looking statements This presentation may contain forward-looking
AMGEN AT ASH 2017: DEVELOPING LEADERSHIP IN BISPECIFIC THERAPIES DECEMBER 9, 2017
AMGEN AT ASH 2017: DEVELOPING LEADERSHIP IN BISPECIFIC THERAPIES DECEMBER 9, 2017 SAFE HARBOR STATEMENT This presentation contains forward-looking statements that are based on management s current expectations
Introducing a First-in-Class treatment for Non-Hodgkin Lymphoma BioEquity Europe 2016, Copenhagen May 11, 2016 Luigi Costa, Chief Executive Officer
Introducing a First-in-Class treatment for Non-Hodgkin Lymphoma BioEquity Europe 2016, Copenhagen May 11, 2016 Luigi Costa, Chief Executive Officer Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo,
Multiple Myeloma Research Consortium Clinical Trial Pipeline
Multiple Myeloma Research Consortium Clinical Trial Pipeline Phase 2 Trial of Combination of Elotuzumab and Lenalidomide +/- Dexamethasone in High-Risk Smoldering Multiple Myeloma NCT02279394 High-Risk
Biologics Market: Where Are We Now? Where Are We Going?
Biologics Market: Where Are We Now? Where Are We Going? Rakesh Dixit, Ph.D., DABT Vice President, Research & Development AstraZeneca-Medimmune Biologics R & D Scope of Biologics Medicines Biotechnology
UNUM THERAPEUTICS CORPORATE PRESENTATION APRIL 2019
UNUM THERAPEUTICS CORPORATE PRESENTATION APRIL 2019 FORWARD-LOOKING STATEMENTS AND RISK FACTORS This presentation and the accompanying oral commentary contain forward-looking statements that involve risks,
CAR-T Cells enter center stage!
CAR-T Cells enter center stage! COSTEM, Berlin, October 2017 Molmed sponsored symposium»approaches to potentially overcome CAR-T cell toxicity: anticytokine antibodies and suicide genes" Christian CHABANNION
DEVELOPING FIRST-IN-CLASS TREATMENTS IN HAEMATOLOGIC CANCERS
DEVELOPING FIRST-IN-CLASS TREATMENTS IN HAEMATOLOGIC CANCERS DEUTSCHE BANK 42ND ANNUAL HEALTH CARE CONFERENCE MAY 4, 2017 LUIGI COSTA, CEO Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway www.nordicnanovector.com
Multiple Myeloma Highlights From the 2015 ASCO Annual Meeting and the 20 th Congress of EHA
Multiple Myeloma Highlights From the 2015 ASCO Annual Meeting and the 20 th Congress of EHA July 13, 2015 Welcome and Introductions Anne Quinn Young, MPH Multiple Myeloma Research Foundation Norwalk, CT
GENENTECH PROVIDES UPDATE ON PIPELINE AGENTS AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY MEETING
NEWS RELEASE Media Contact: Krysta Pellegrino (650) 225-8226 Investor Contact: Diane Schrick (650) 225-1599 Advocacy Contact: Kristin Reed (650) 467-9831 GENENTECH PROVIDES UPDATE ON PIPELINE AGENTS AT
Pre-ASH POV: Efficient Clinical Trial and Approval Strategies in Oncology
Pre-ASH POV: Efficient Clinical Trial and Approval Strategies in Oncology A PRECISION PERSPECTIVE A Pre- ASH POV: Efficient Clinical Trial and Approval Strategies in Oncology Gerald L. Messerschmidt, MD,
Investor Update. Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting
Investor Update Basel, 1 November 2017 Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting Further results from emicizumab phase III
CD19 ADCs Effectively Targeting B Cell Malignancies a clinical perspective.
CD19 ADCs Effectively Targeting B Cell Malignancies a clinical perspective. Martin J.S. Dyer Helen and Ernest Scott Haematological Research Institute University of Leicester Dyer Financial Disclosures
Immune Design Reports Third Quarter 2017 Financial Results and Provides Corporate Update
November 1, 2017 Immune Design Reports Third Quarter 2017 Financial Results and Provides Corporate Update Company conference call at 1:30 p.m. PT today SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 01,
Relapsed/Refractory Multiple Myeloma: Standard of Care Among Emerging Agents
Welcome to Managing Myeloma. My name is Adam Cohen, and I am the Director of Myeloma Immunotherapy and an Assistant Professor in the Hematology/Oncology Division at Abramson Cancer Center of the University
Management of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation in the Era of Novel Therapies Larry Anderson, MD, PhD Multiple Myeloma and Stem Cell Transplant
The Multiple Myeloma Research Foundation Webinar Series Improving the Overall Understanding of Immunotherapy in Multiple Myeloma
Improving the Overall Understanding of Immunotherapy in Multiple Myeloma Webinar 1, August 13, 2015 Antibodies: The Body s Foot Soldiers in the Battle Against Disease Speakers Moderator: Joseph Mikhael,
Conference Call L-MIND data
DECEMBER 12, 2017 Conference Call L-MIND data MorphoSys AG Today on the Call Dr. Simon Moroney Dr. Malte Peters Jens Holstein Anke Linnartz CEO CDO CFO Head of Corporate Communications & IR MorphoSys AG,
Translational development of Therapeutic Lymphoma Vaccines
Translational development of Therapeutic Lymphoma Vaccines Larry W. Kwak, M.D., Ph.D. Chairman, Department of Lymphoma/Myeloma Justin Distinguished Chair in Leukemia Research Assoc. Director, Center for
Multiple Myeloma at ASH Kevin Song MD, FRCPC Vancouver General Hospital Leukemia/BMT Program of BC Vancouver, British Columbia
Multiple Myeloma at ASH 2017 Kevin Song MD, FRCPC Vancouver General Hospital Leukemia/BMT Program of BC Vancouver, British Columbia Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy:
This talk will cover. New insights and future directions. Dr Hannah Hunter Consultant Haematologist University Hospitals Plymouth NHS Trust
This talk will cover New insights and future directions Dr Hannah Hunter Consultant Haematologist University Hospitals Plymouth NHS Trust An overview of current research areas o Understanding who gets
Immunotherapy in myeloma
Immunotherapy in myeloma This Horizons Infosheet contains information on immunotherapy, a type of treatment being investigated in myeloma. The Horizons Infosheet series provides information relating to
Multiple myeloma breakthrough 2018
Multiple myeloma breakthrough 2018 Carfilzomib Can Lead to Cardiovascular Toxicity in Multiple Myeloma Patients. Get the latest science news with ScienceDaily's free email newsletters, updated daily and
Developing First-in-Class Treatments in Haematologic Cancers DNB Healthcare Conference, Thursday December 15 th, 2016
Developing First-in-Class Treatments in Haematologic Cancers DNB Healthcare Conference, Thursday December 15 th, 2016 \\AD.JEFCO.COM\BANKING\HEALTHCARE INTL\DEALS\NOR45600IB - TARGET\2. FROM COMPANY\011216
Immunotherapy in myeloma
Immunotherapy in myeloma Horizons Infosheet Clinical trials and novel drugs This Horizons Infosheet provides information on immunotherapy, a type of treatment being investigated in myeloma. The Horizons
Advancing Manufacturing for Advanced Therapies
Advancing Manufacturing for Advanced Therapies Peter Marks, MD, PhD Center For Biologics Evaluation and Research, FDA CASSS Cell & Gene Therapy Symposium July 10, 2018 Overview Cell and gene therapy products
Jefferies Healthcare Conference. June 2016
Jefferies Healthcare Conference June 2016 Forward Looking Statements This presentation contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation
Application supported by the Phase 3 MAIA study being reviewed under the FDA Real-Time Oncology Review pilot program
Media Inquiries: Satu Glawe Phone: +49 172 294 6264 Bernadette King Phone: 1-215-778-3027 Investor Relations: Christopher DelOrefice Phone: 1-732-524-2955 Lesley Fishman Phone: 1-732-524-3922 U.S. Medical
CAR T CELL THERAPY FOR MYELOMA MAUNG MYO HTUT, MD
CAR T CELL THERAPY FOR MYELOMA MAUNG MYO HTUT, MD Disclosures I do not have anything to disclose CAR T cell targets in multiple myeloma (MM) Targets Rationale Trials CD19 Kappa CD138 BCMA CS1 (SLAMF7)
REVOLUTIONARY SCIENCE MEETS TRANSFORMATIVE CANCER THERAPY PHARMACY FELLOWSHIP PROGRAM
REVOLUTIONARY SCIENCE MEETS TRANSFORMATIVE CANCER THERAPY. 2018 PHARMACY FELLOWSHIP PROGRAM EMPOWERING ANTIBODIES, TARGETING CANCER Seattle Genetics is the largest global oncology biotechnology company
Princess Margaret Cancer Centre Multiple Myeloma Day Introduction. Anca Prica MD, MSc, FRCPC May 12, 2017
Princess Margaret Cancer Centre Multiple Myeloma Day Introduction Anca Prica MD, MSc, FRCPC May 12, 2017 Who are you? 1) Physician 2) Nurse 3) Pharmacist 4) Trainee 5) Other How many times have you been
kinderkrebsinfo.de (htt / Health professional / Clinical Trials (https / Phase I / II Trials in / Inotuzumab Ozoga
English translations are still in development. If you can't find the information you need, please try later and/or contact us in your language via our contact form (./../../../../about_us/contact/index_eng.html)
Community Oncologists Perception and Adaptability to Emerging Chimeric Antigen T-cell (CAR-T) Therapy
research report Community Oncologists Perception and Adaptability to Emerging Chimeric Antigen T-cell (CAR-T) Therapy Chadi Nabhan, MD, MBA, FACP; Yolaine Jeune-Smith, PhD; Peter Klinefelter, BA; Jennifer
What do you do, with an M protein?
What do you do, with an M protein? Cancer Day for Primary Care Emily Rimmer MD FRCPC January 31, 2014 emily.rimmer@cancercare.mb.ca Disclosure of Potential for Conflict of Interest Name of presenter: Emily
Genmab Announces U.S. FDA Approval of DARZALEX (daratumumab) for Relapsed Multiple Myeloma and Updates Financial Guidance
Company Announcement DARZALEX (daratumumab) approved by U.S. FDA in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone for relapsed or refractory multiple myeloma Financial
PARADIGME UPDATE APRIL Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway IR contact:
PARADIGME UPDATE APRIL 2018 Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway www.nordicnanovector.com IR contact: ir@nordicnanovector.com Key messages Revised timelines for PARADIGME data read-out
Salvage Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma
Salvage Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma Arnon Nagler, M.D., M.Sc Director Hematology Division BMT and Cord Blood Bank Chair Israeli BMT Association Chaim Sheba Medical Center,
Corporate Presentation. April 2016
Corporate Presentation April 2016 1 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Update from the Center for Biologics Evaluation and Research (CBER) Peter Marks, M.D., Ph.D. GMP By The Sea 2017
Update from the Center for Biologics Evaluation and Research (CBER) Peter Marks, M.D., Ph.D. GMP By The Sea 2017 Outline Products regulated Significance of complex biologics Product and process Cutting
Changing Lives. Daniel Junius, President and CEO June 3, Nasdaq: IMGN
Changing Lives Daniel Junius, President and CEO June 3, 215 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These
Challenges in Capturing Long Term Follow up of Recipients of Genetically Modified Cells. Cell Therapy Liaison Meeting January, 2018
Challenges in Capturing Long Term Follow up of Recipients of Genetically Modified Cells Cell Therapy Liaison Meeting January, 2018 Outline Development of the Cellular Therapy Registry Standardized Data
Restrooms Cell phones on silent/vibrate. Refreshments. Patient resource materials
Restrooms Cell phones on silent/vibrate Refreshments Patient resource materials This presentation should not replace discussions with your healthcare provider, but seeks to provide information and resources
Changing the Practice of Cancer Treatment. 36 th Annual J.P. Morgan Healthcare Conference Hervé Hoppenot, Chief Executive Officer January 8, 2018
Changing the Practice of Cancer Treatment 36 th Annual J.P. Morgan Healthcare Conference Hervé Hoppenot, Chief Executive Officer January 8, 2018 Forward-looking Statements Except for the historical information
Evaluation of AMG 531 Efficacy in Splenectomized Patients with Chronic ITP in a Randomized Placebo- Controlled Phase 3 Study
Evaluation of AMG 531 Efficacy in Splenectomized Patients with Chronic ITP in a Randomized Placebo- Controlled Phase 3 Study Plenary Session at ASH 2007 Presented by Terry B. Gernsheimer Madeleine Verhovsek
Genitope Corporation. Summary of MyVax Personalized Immunotherapy Phase 3 Clinical Trial Results
Genitope Corporation Summary of MyVax Personalized Immunotherapy Phase 3 Clinical Trial Results Introduction In December 27, Genitope Corporation ( Genitope ) obtained data indicating that its pivotal
POST-ASH Issue 2, Lenalidomide and Rituximab for Untreated Indolent Lymphoma: Final Results of a Phase II Study
POST-ASH Issue 2, 2013 Lenalidomide and Rituximab for Untreated Indolent Lymphoma: Final Results of a Phase II Study For more visit ResearchToPractice.com/5MJCASH2013 CME Information OVERVIEW OF ACTIVITY
The industry s largest toolkit with
19 targets supported by GENETIC VALIDATION The industry s largest toolkit with 9 MODALITIES A mix of INNOVATIVE MOLECULES, NEW INDICATIONS, AND BIOSIMILARS A robust and differentiated pipeline, leveraging
NEXT-GENERATION CAR T-CELLS AGAINST CANCER. Gene-Edited Off-The-Shelf Immunotherapies
NEXT-GENERATION CAR T-CELLS AGAINST CANCER Gene-Edited Off-The-Shelf Immunotherapies Forward-looking Statements This presentation contains forward-looking statements that are based on our management s
Actinium Pharmaceuticals, Inc.
, Inc. CD33 Program Overview and Update Introducing Combination Study of Actimab-A + CLAG-M February 13, 2018 1 Disclaimer and Safe Harbor Some of the information presented herein may contain projections
Oncology Insights: December 2017
Cardinal Health Specialty Solutions Oncology Insights: December 2017 Views on New and Emerging Therapies From Specialty Physicians Nationwide A message from the President Joe DePinto Welcome to the second
Nonclinical Data to Support FIH Clinical Trials for Cancer Immunotherapies. Whitney S. Helms, PhD IOM, February 29,2016
Nonclinical Data to Support FIH Clinical Trials for Cancer Immunotherapies Whitney S. Helms, PhD IOM, February 29,2016 Disclaimer The views disseminated in this talk are my own and do not necessarily represent
Trubion Investor Presentation BioCentury NewsMakers in the Biotech Industry Conference September 6, 2007
Trubion Investor Presentation BioCentury NewsMakers in the Biotech Industry Conference September 6, 2007 Peter Thompson, M.D., FACP President, CEO and Chairman Trubion Pharmaceuticals, Inc. Safe Harbor
NEXT-GENERATION CAR T-CELLS AGAINST CANCER. Gene-Edited Off-The-Shelf Immunotherapies
NEXT-GENERATION CAR T-CELLS AGAINST CANCER Gene-Edited Off-The-Shelf Immunotherapies Forward-looking Statements This presentation contains forward-looking statements that are based on our management s
ANTIBODY THERAPY ANTIBODY THERAPY ANTIBODY THERAPY PDF MONOCLONAL ANTIBODY THERAPY - WIKIPEDIA ANTIBODY - WIKIPEDIA 1 / 5
PDF MONOCLONAL - WIKIPEDIA ANTIBODY - WIKIPEDIA 1 / 5 2 / 5 3 / 5 antibody therapy pdf Monoclonal antibody therapy is a form of immunotherapy that uses monoclonal antibodies (mab) to bind monospecifically
Deborah Dunsire, M.D. President and CEO. Annual Meeting of Shareholders Cambridge, MA May 4, 2006
Deborah Dunsire, M.D. President and CEO Annual Meeting of Shareholders Cambridge, MA May 4, 2006 2006 Millennium 2006 Pharmaceuticals Millennium Inc. Pharmaceuticals, Inc. Agenda 2005 Key Accomplishments
Management of Multiple Myeloma: The Changing Paradigm. Clinical Trials
Management of Multiple Myeloma: The Changing Paradigm Clinical Trials Goal of Clinical Trials: Making Progress Against Myeloma Increase understanding of the disease Improve the way we use currently available
CORPORATE OVERVIEW: REINVENTING THERAPEUTIC ANTIBODIES FOR THE TREATMENT OF CANCER
CORPORATE OVERVIEW: REINVENTING THERAPEUTIC ANTIBODIES FOR THE TREATMENT OF CANCER March 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements
Management of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm Relapsed/Refractory Disease Jeffrey A. Zonder, MD Karmanos Cancer Institute Objectives Discuss use of standard myeloma therapies when used as therapy
DEVELOPING PRECISION THERAPIES IN HAEMATOLOGIC CANCERS
DEVELOPING PRECISION THERAPIES IN HAEMATOLOGIC CANCERS DNB HEALTHCARE CONFERENCE DECEMBER 14 TH, 2017 LUIGI COSTA, CEO Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway www.nordicnanovector.com
Managing Patients with Multiple Myeloma: What the Specialty Pharmacist Needs to Know
Managing Patients with Multiple Myeloma: What the Specialty Pharmacist Needs to Know Disclaimer: The information within this CME/CE activity is for continuing education purposes only, and is not intended
Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed, or Relapsed and Refractory Multiple Myeloma
Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed, or Relapsed and Refractory Multiple Myeloma Torben Plesner 1, Hendrik-Tobias Arkenau 2, Henk M Lokhorst 3, Peter Gimsing
Antibody-Based Immunotherapy of Lymphoma
Antibody-Based Immunotherapy of Lymphoma Immunology Department Student Lecture March 31, 2015 Myron S. Czuczman, MD Chief, Lymphoma/Myeloma Service Head, Lymphoma Translational Research Lab Roswell Park
chronic leukemia lymphoma myeloma differentiated 14 September 1999 Transformed Pre- Ig Surface Surface Secreted B- ALL Macroglobulinemia Myeloma
Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pre- B-cell B-cell Transformed B-cell Plasma cell Ig Surface Surface Secreted Major malignant counterpart
To the Reviewers: POINT-BY-POINT REPLY
To the Reviewers: We changed our manuscript according to the Reviewer s suggestions. We used a red character for the novel information added or for the sentences deleted from the original version of the
Patient Case and Question
Management of Multiple Myeloma: The Changing Paradigm Relapsed/Refractory Disease Kenneth H. Shain, MD, PhD Assistant Member H. Lee Moffitt Cancer Center Assistant Professor University of South Florida
Novel Cell-Based Assays to Accelerate Cancer Immunotherapies. Abhi Saharia, Ph. D. Director, Cell-Based Assays
Novel Cell-Based Assays to Accelerate Cancer Immunotherapies Abhi Saharia, Ph. D. Director, Cell-Based Assays 1 ionc drugs Powerful Cancer Treatments Clinical success of Checkpoint mabs from Merck & BMS
Lecture 9: Antibodies & Antibody Conjugates - targeted cell killing agents
Lecture 9: Antibodies & Antibody Conjugates - targeted cell killing agents Monoclonal antibodies, whether they are naked or conjugated can be identified quickly by the mab at the end of their name. Furthermore,
INTERIM RESULTS AS OF MARCH 31, 2017
INTERIM RESULTS AS OF MARCH 31, 2017 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of
Affimed: Developing First-In-Class Immune Cell Engagers for the Activation of Innate and Adaptive Immunity to Fight Cancer
Affimed: Developing First-In-Class Immune Cell Engagers for the Activation of Innate and Adaptive Immunity to Fight Cancer Corporate Presentation May 2018 Forward-looking statements / safe harbor This
بسم اهلل الرمحن الرحيم
بسم اهلل الرمحن الرحيم Definition Multiple myeloma is a neoplastic plasma cell dyscrasia (PCD) that generally produced a monoclonal immunoglobulin protein, characterized by a clinical pentad: (a) anemia;
Treatment options in Myeloma. BritModis myeloma for the elderly care specialist
Treatment options in Myeloma myeloma for the elderly care specialist Dr Richard Soutar, Consultant in Haematology and Transfusion Medicine, Beatson Oncology Centre, Glasgow and The Scottish National Blood
Review Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma
Review Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma Shih-Feng Cho 1,2,3, Liang Lin 3, Lijie Xing 3,4, Tengteng Yu 3, Kenneth Wen 3, Kenneth C. Anderson 3 and Yu-Tzu Tai 3, * 1
Regulatory Pathways for Rare Diseases
Regulatory Pathways for Rare Diseases Celia M. Witten, Ph.D., M.D. Deputy Director, FDA Center for Biologics Evaluation and Research Emerging Technologies for Rare Diseases: Clinical and Regulatory Case
POST-ASH Issue 2, Bendamustine/Rituximab and Maintenance Lenalidomide in Relapsed/Refractory CLL and SLL
POST-ASH Issue 2, 2013 Bendamustine/Rituximab and Maintenance Lenalidomide in Relapsed/Refractory CLL and SLL For more visit ResearchToPractice.com/5MJCASH2013 CME Information OVERVIEW OF ACTIVITY The
DEVELOPING FIRST-IN-CLASS TREATMENTS IN HAEMATOLOGIC CANCERS
DEVELOPING FIRST-IN-CLASS TREATMENTS IN HAEMATOLOGIC CANCERS JEFFERIES GLOBAL HEALTHCARE CONFERENCE JUNE 8, 2017 LUIGI COSTA, CEO Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway www.nordicnanovector.com
Results FY2017 & Outlook 2018
March 13, 2018 Results FY2017 & Outlook 2018 MorphoSys AG Today on the Call Dr. Simon Moroney Jens Holstein Dr. Malte Peters Chief Executive Officer Chief Financial Officer Chief Development Officer 2
Better Antibodies By Design. 36 th Annual J.P. Morgan Healthcare Conference January 10, 2018
Better Antibodies By Design 36 th Annual J.P. Morgan Healthcare Conference January 10, 2018 Forward Looking Statement This presentation contains forward looking statements. The words believe, expect, anticipate,
FORWARD-LOOKING STATEMENTS
1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual
7/6/2017. Learning Objectives
Learning Objectives Monoclonal Antibody Therapeutics Potential Interferents on Protein Electrophoresis and Related Tests Maria Alice V. Willrich, Ph.D., DABCC At the end of the presentation, participants
Neulasta Fulphila. Neulasta (pegfilgrastim), Fulphila (pegfilgrastim-jmdb) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.09 Subject: Neulasta Fulphila Page: 1 of 5 Last Review Date: September 20, 2018 Neulasta Fulphila
Immunodiscovery developing antibodies for research, diagnosis and therapy MATS OHLIN
Immunodiscovery developing antibodies for research, diagnosis and therapy MATS OHLIN Immunotechnology a department at Lund University exploiting advanced technologies in biomedicine Genomics Antibody technology